India launches 7th National Formulary of India 2026 and approves biovigilance programme for transplant-related adverse events The Health Ministry unveiled updated medicine-safety guidance, a medical-device adverse-event framework and expanded surveillance of adverse events linked to organ and tissue transplantation. Society · 22 Sep 2026 · GS: GS2, GS3, Essay · Exam yield: High WHY THIS MATTERS This story expands India’s patient-safety system from medicines to medical devices and transplant-related biological products. For UPSC, it links public health, rational drug use, regulatory capacity, digital governance, organ transplantation and India’s growing contribution to global health evidence. IN PLAIN WORDS This development sits within India’s wider patient-safety system: medicines are monitored through pharmacovigilance, medical devices through materiovigilance, and transplant-related medicines and biological products through the newly approved Biovigilance Programme of India. On 21 September 2026, the Indian Pharmacopoeia Commission launched the 7th National Formulary of India, a hospital guidance document, and a mobile reporting application. (pib.gov.in) The National Formulary of India 2026 helps health professionals choose and use medicines rationally. Its 34 chapters, 20 appendices and 653 drugs include 42 fixed-dose combinations and 30 immunologicals; drug descriptions have been revised to align with the National List of Essential Medicines and national health programmes. The Biovigilance Programme will help report, assess, monitor and prevent harmful events linked to medicines and biological products used for organ and tissue transplantation, including products given to donors and recipients. (pib.gov.in) Think of the system as a nationwide early-warning network: a doctor, nurse or patient reports a suspected problem; experts examine patterns; regulators can then issue warnings, change instructions or take other action. The new medical-device guidance and ADR-PvPI 2.0 iOS application widen reporting channels. India now has around 1,150 adverse-drug-reaction reporting centres, but the government wants to extend the network to primary healthcare and increase patient participation. (pib.gov.in) KEY FACTS • The 7th edition of the National Formulary of India was launched by Union MoS for Health and Family Welfare Anupriya Patel. • The formulary’s drug monographs were revised to align with the National List of Essential Medicines and national health programmes. • The government approved the Biovigilance Programme of India, with the Indian Pharmacopoeia Commission leading monitoring of adverse events related to organ and tissue transplantation. • A guidance document for reporting medical-device-related adverse events and the ADR-PvPI 2.0 iOS mobile application were also launched. • India’s contribution to the WHO patient-safety database reportedly rose from 123rd to 8th globally, with around 1,150 adverse-drug-reaction reporting centres operational. HOW WE GOT HERE India’s medicine-safety framework evolved from a mainly product-approval model towards continuous monitoring after products enter public use. The World Health Organization established its international drug-monitoring programme in 1968 after the 1963 World Health Assembly called for systematic collection of serious adverse drug reactions. (who.int) In India, the nationwide Pharmacovigilance Programme of India was initiated in July 2010, initially with the All India Institute of Medical Sciences as the national coordinating centre. In April 2011, coordination shifted to the Indian Pharmacopoeia Commission at Ghaziabad. The Materiovigilance Programme of India was approved in 2015 and formally launched on 6 July 2015 to monitor medical-device-related adverse events. (ipc.gov.in) The National Formulary of India has been published periodically by the Indian Pharmacopoeia Commission since 2009. The 2026 edition therefore represents an incremental strengthening of an existing system, not a completely new prescribing institution. Its new transplant-focused biovigilance component fills an important safety gap because transplant patients and donors may face risks from immunosuppressive medicines, biological products, procedures and interactions across multiple stages of care. (pib.gov.in) THE BIGGER PICTURE Social — Patient safety and public trust The central social benefit is that patients become participants in safety surveillance rather than passive recipients of treatment. Adverse drug reactions are often under-reported because patients may not recognise them, health workers may lack time, or people may fear blame. The government’s emphasis on mobile reporting, helplines and patient participation can improve the evidence base. However, digital-only reporting may exclude people without smartphones, reliable connectivity or health literacy. Expansion to primary healthcare, regional languages and assisted reporting is therefore essential for equity. Around 1,150 reporting centres provide a base, but coverage must translate into usable, representative data. (pib.gov.in) → Patient safety improves only when reporting is easy, trusted, inclusive and acted upon. Science & Tech — From isolated reports to safety signals Pharmacovigilance is not merely counting side effects; it involves detecting patterns, assessing whether a product may have caused an event, understanding risks and preventing recurrence. The new framework combines medicine, device and transplant-related surveillance. Digital systems such as NFI Online, ADR-PvPI 2.0 and the Adverse Drug Reaction Monitoring System can speed data collection and analysis. Artificial intelligence may help identify unusual patterns, but automated signals require expert validation because a reported event does not automatically prove that a product caused it. (pib.gov.in) → Technology can accelerate detection, but scientific causality assessment must remain human-supervised. Economic — Reducing avoidable healthcare costs Unsafe medicines, device failures and transplant-related complications can prolong hospitalisation, require additional treatment and reduce patient productivity. Better surveillance can support earlier warnings, safer prescribing and more efficient allocation of public-health resources. The National Formulary also promotes rational use, meaning the right medicine, dose, duration and route for a patient’s condition. Yet compliance requires training, functioning reporting systems and regulatory follow-up; otherwise the programme may generate data without reducing costs. Industry may face higher compliance expenses, but these are balanced by fewer preventable harms and stronger confidence in Indian health products. (pib.gov.in) → Safety surveillance is a health investment because prevention is usually cheaper than managing avoidable harm. Constitutional — Public health, dignity and state responsibility Public health is primarily a state subject under the Seventh Schedule, but medicine regulation, standards and national programmes require strong Union coordination. The framework reflects the state’s responsibility to protect life, health and dignity through safe healthcare, while also supporting access to essential medicines. The constitutional challenge is balance: excessive caution can restrict access to useful treatments, whereas weak surveillance exposes citizens to avoidable risks. A transparent system should explain uncertainty, protect patient confidentiality and provide remedies when harm is established. (pib.gov.in) → The policy must reconcile access to treatment with the state’s duty to minimise preventable medical harm. International — India as a contributor to global safety evidence India’s large and diverse patient population can generate valuable evidence about medicine safety across different diseases, genetic backgrounds and healthcare settings. The Health Ministry reported that India’s contribution to the World Health Organization patient-safety database rose from 123rd during 2009–2014 to 8th globally, while around 25 countries recognise the Indian Pharmacopoeia. This strengthens India’s regulatory credibility and supports its ambition to be a global pharmaceutical leader. The figures are government-reported and should be interpreted as evidence of reporting contribution, not proof that Indian medicines are inherently safer. (pib.gov.in) → India’s strategic advantage is converting its pharmaceutical scale into credible, internationally useful safety evidence. THE BIG DEBATE Will expanding vigilance programmes substantially improve patient safety, or mainly create another reporting layer? For: • More reporting centres and digital tools can reveal rare or delayed harms that pre-market clinical trials may miss. • A single framework covering medicines, devices and transplant products enables cross-sector safety signals and coordinated regulatory action. • The National Formulary can reduce irrational prescribing by linking clinical practice with updated medicine standards. • Patient reporting makes surveillance more democratic and captures experiences often missed by hospital-based systems. Against: • Reports may be incomplete, duplicated or unverified, creating false alarms and weakening confidence in the system. • Digital applications may exclude rural, elderly, poor or digitally illiterate patients, worsening data bias. • Without mandatory institutional follow-up, trained staff and regulatory action, reporting may become a symbolic exercise. • Excessive caution can delay access to beneficial medicines, devices or transplant therapies. The balanced take: Expansion is justified because post-market risks cannot be fully predicted through trials, especially for rare events and diverse populations. However, reporting volume is not the same as safety improvement. The programme will succeed only if India closes the chain from accessible reporting to expert assessment, transparent communication, corrective action and patient redress. ANSWER IT IN MAINS Discuss the importance of pharmacovigilance in ensuring safe and rational use of medicines in India. (GS2) How to attack it: Begin with the shift from pre-market testing to lifelong safety monitoring. Explain reporting, signal detection and regulatory response; assess under-reporting, capacity and digital inclusion; conclude with patient-centred, primary-care-led surveillance. Quote this: WHO Programme for International Drug Monitoring definition of pharmacovigilance; Pharmacovigilance Programme of India objectives; around 1,150 reporting centres reported in PIB, 21 September 2026. (who.int) How can India balance access to medicines with patient safety and regulatory caution? (GS2) How to attack it: Frame access and safety as complementary parts of healthcare justice. Analyse essential-medicine guidance, benefit-risk assessment, post-market monitoring, affordability and transparency; conclude that evidence-based regulation protects both access and trust. Quote this: 7th National Formulary of India 2026 aligned with the National List of Essential Medicines and national health programmes. (pib.gov.in) Examine the role of technology in strengthening public-health surveillance in India. (GS3) How to attack it: Use ADR-PvPI 2.0, NFI Online and the Adverse Drug Reaction Monitoring System as examples. Discuss speed, interoperability, artificial-intelligence opportunities, privacy, bias and human validation; conclude with accountable digital public infrastructure. Quote this: PIB, 21 September 2026, on NFI Online, ADR-PvPI 2.0, ADRMS, artificial intelligence and expansion to primary healthcare. (pib.gov.in) Patient participation is the missing link in medicine safety. Discuss. (Essay) How to attack it: Open with the idea that lived patient experience reveals harms invisible to short clinical trials. Cover awareness, trust, language, digital divide, confidentiality and feedback loops; conclude that reporting must lead to action, not merely data accumulation. Quote this: WHO explains that post-market use among larger and more diverse populations can reveal side effects not visible in clinical trials; India has called for greater patient reporting. (who.int) PRELIMS QUICK-FIRE • [Data] National Formulary of India 2026 contains 34 chapters, 20 appendices and 653 drugs, including 42 fixed-dose combinations and 30 immunologicals. (pib.gov.in) — NFI is a guidance document for rational use; it is not the same as the Indian Pharmacopoeia’s quality standards. • [Body/Institution] The National Formulary of India has been published periodically by the Indian Pharmacopoeia Commission since 2009. (pib.gov.in) — The publishing institution is IPC, not the World Health Organization or a private medical association. • [Scheme] Pharmacovigilance Programme of India began nationwide in July 2010; coordination shifted from AIIMS to IPC in April 2011. (ipc.gov.in) — PvPI monitors medicine-related adverse events; it is not primarily a procurement scheme. • [Scheme] Materiovigilance Programme of India was approved in 2015 and formally launched on 6 July 2015 for medical-device safety monitoring. (ipc.gov.in) — Materiovigilance concerns devices, while pharmacovigilance concerns medicines. • [Scheme] Biovigilance Programme of India will monitor adverse events linked to transplant-related medicines and biological products for donors and recipients. (pib.gov.in) — Biovigilance here is broader than only monitoring donated organs; it includes associated medicines and biological products. • [Data] Around 1,150 adverse-drug-reaction reporting centres operate across public and private hospitals and medical colleges. (pib.gov.in) — The figure refers to reporting centres, not the number of adverse reactions or hospitals in India. • [Report/Index] India reportedly moved from 123rd during 2009–2014 to 8th globally in contributions to the WHO patient-safety database. (pib.gov.in) — This indicates reporting contribution, not a global ranking of medicine quality or overall healthcare safety. • [Term] The 7th National Formulary of India is available digitally through NFI Online alongside the print edition. (pib.gov.in) — Digital availability improves access but does not by itself ensure adoption by prescribers. WHAT SHOULD HAPPEN 1. Make reporting routine at primary healthcare facilities through trained nodal personnel, multilingual forms, helplines and assisted patient reporting. Decentralisation will reduce urban and hospital bias and bring safety surveillance closer to the populations using medicines and devices. (WHO Programme for International Drug Monitoring and the government’s 2026 announcement to expand reporting to primary healthcare. (who.int)) 2. Create interoperable, privacy-protecting data systems connecting medicine, device, transplant and blood-product surveillance. A common data architecture can identify interactions and repeated safety signals across different products and stages of care. (Indian Pharmacopoeia Commission’s stated plan for digitally enabled vigilance covering medicines, medical devices, blood and blood products and other medical products. (pib.gov.in)) 3. Use artificial intelligence only as a screening aid, followed by expert causality assessment, independent review and transparent communication. Algorithms can detect patterns rapidly but cannot alone establish whether a product caused an adverse event. (WHO definition and objectives of pharmacovigilance, which require detection, assessment, understanding and prevention of medicine-related problems. (who.int)) 4. Link reports to regulatory action, periodic safety updates, corrective instructions, procurement decisions and patient compensation mechanisms where appropriate. A reporting system earns public trust only when information produces visible improvements in clinical practice and accountability. (Pharmacovigilance Programme of India objectives on evidence generation, regulatory recommendations and communication of safety information. (ipc.gov.in)) JARGON, DEMYSTIFIED • National Formulary of India (NFI) — A professional guidance document that helps healthcare workers select and use medicines safely, rationally and according to national priorities. (It guides clinical use; it is not a legally exhaustive list of every medicine available.) • Indian Pharmacopoeia Commission (IPC) — A Ministry of Health institution responsible for medicine standards and coordination of major safety-monitoring programmes in India. (IPC coordinates the national medicine-safety centre and leads the newly approved transplant-related biovigilance programme.) • Pharmacovigilance — The science and activities used to detect, assess, understand and prevent harmful effects or other problems related to medicines. (It continues after approval and public use of a medicine.) • Adverse drug reaction (ADR) — A harmful and unintended response to a medicine taken at normally used doses; it is more specific than any unwanted medical event. (A reported ADR is suspected evidence, not automatic proof that the medicine caused the harm.) • Materiovigilance Programme of India (MvPI) — India’s system for collecting and analysing harmful events or risks associated with medical devices and supporting regulatory action. (It was formally launched on 6 July 2015.) • Biovigilance Programme of India — A safety-monitoring system for medicines and biological products used in organ and tissue transplantation, including products given to donors and recipients. (Its approved scope in this story is transplant-related safety surveillance.) • National List of Essential Medicines (NLEM) — India’s official list of medicines considered necessary for priority health needs, based on public-health relevance, effectiveness, safety and affordability. (NFI 2026 drug descriptions were revised for alignment with NLEM and national health programmes.) REVISE IN 30 SECONDS • NFI 2026: 34 chapters, 20 appendices, 653 drugs, 42 fixed-dose combinations and 30 immunologicals. (pib.gov.in) • Biovigilance adds transplant-related medicines and biological products to India’s safety-monitoring architecture. (pib.gov.in) • PvPI began nationwide in July 2010; coordination shifted from AIIMS to IPC in April 2011. (ipc.gov.in) • MvPI monitors medical-device-related adverse events and was formally launched on 6 July 2015. (ipc.gov.in) • Around 1,150 adverse-drug-reaction reporting centres are operational, with planned expansion to primary healthcare. (pib.gov.in) • Core UPSC theme: access to medicines must be combined with quality, rational use, safety and accountability. STUDY NEXT Static links: Right to health and public-health governance, Essential medicines and rational drug use, Regulation of medicines, medical devices and biological products, Digital health and patient safety Essay angle: A medicine becomes truly beneficial only when access, quality, rational use and continuous safety monitoring travel together. Interview probe: Ask whether India’s goal should be more reporting, safer products, or stronger action after reports; the best answer connects all three. SOURCES • Anupriya Patel launches 7th National Formulary of India 2026, announces Biovigilance Programme to widen India’s patient-safety net — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2312930&lang=1®=3 Source: India launches 7th National Formulary of India 2026 and approves biovigilance programme for transplant-related adverse events — https://mindsofaspirants.com/current-affairs/kx75asxdnrzp0hfnyegay71v898exxj2
